Telomir Pharmaceuticals, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 |
|---|---|---|---|---|
| Operating expenses | $10.5M | $12.2M | $3.9M | $854,147 |
| Cash from operations | -$3.7M | -$5.1M | -$3.9M | -$468,661 |
| Total assets | $7.3M | $1.3M | $4.8M | $48,730 |
| Total liabilities | $1.4M | $680,968 | $1.3M | $986,008 |
| Total debt | — | $100,000 | $500,000 | $600,000 |
Shares outstanding 68.8M · Free float 81.7%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.